Ignite Creation Date:
2024-07-17 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06481826
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2024-06-12
Brief Title:
Glofitamab in Chinese Patients With RR DLBCL
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
A Study to Evaluate Glofitamab as Single Agent in Chinese Patients With RelapsedRefractory Diffuse Large B-Cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory RR diffuse large B-cell lymphoma DLBCL who have failed two or more lines of systemic therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None